Several potential jurors were excused Monday for comments about Shkreli, including "a very evil man," "a snake," or "the price gouger." » Read More
By: Rachel Cao
Shares of Innate Immunotherapeutics tanked 92 percent to less than 5 Australian cents on Tuesday. » Read More
By: Meg Tirrell
The FDA's new list — designed to spur generic competition to bring down prices or deter gougers — holds a big risk for Valeant. » Read More
By: Dan Mangan
Several potential jurors were excused for comments about Shkreli, including "a very evil man," "a snake," or "the price gouger." » Read More
The price of a pack of life-saving EpiPens shot up to $400. This is out of control, says Jake Novak. But, there IS a solution.
Mylan has increased the price of the anti-allergy device EpiPen more than five-fold in recent years.
Alex Tarrant, assistant editor at Dealreporter Europe, Mergermarket Group, shares his views on the deal between Pfizer and Medivation.
Pharmaceutical firms rely on acquisitions to plug the gap on innovations they do not currently possess, says Albert Fried and Company's Sachin Shah.
Pfizer investors should be concerned about the high premium, while Medivation investors should celebrate, says RBC Capital Markets' Simos Simeonidis.
CNBC's Meg Tirrell reports on the action in the IBB biotech ETF after Pfizer announced it was buying Medivation and what some other big M&A deals could be coming down the line. The "Fast Money" traders weigh in.
CNBC's Meg Tirrell reports on shares of EpiPen maker Mylan dropping following increasing questions over its pricing. The "Fast Money" traders weigh in.
A growing chorus is calling on the Mylan pharmaceutical company to justify its price hikes on EpiPens, NBC News reports.
Iowa Senator Chuck Grassley sends a letter to Mylan CEO Heather Bresch about EpiPen pricing. CNBC's Meg Tirrell reports.
As biotech stocks rally, Chad Morganlander, Stifel Nicolaus, and Jonathan Krinsky, MKM Partners, share their take on the biotech sector.
CNBC's Meg Tirrell reports the details on Pfizer's deal for Medivation.
CNBC's Meg Tirrell discusses the latest healthcare mergers and acquisitions.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
Pfizer buys Medivation for $14 billion in cash. CNBC's Meg Tirrell reports the latest.
Medivation surged more than 19 percent Monday after Pfizer said it would buy the cancer drug company for about $14 billion.
Pfizer is reportedly near a deal to acquire cancer drug company Medivation for approximately $14 billion, reports CNBC's Meg Tirrell.
Pfizer is in advanced talks to acquire Medivation for close to $14 billion, as it seeks to boost its oncology portfolio.
A growing number of people is calling on the Mylan pharmaceutical company to justify its price hikes on EpiPens, NBC News reports.
Shares of Mylan are under pressure as word spreads about the increased price of its EpiPen drug by 500 percent. David Maris, Wells Fargo managing director, shares his take.
The FDA approves two transcatheter heart valves manufactured by Edwards Lifesciences, CNBC's Seema Mody reports.
Get the best of CNBC in your inbox